X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Xgeva (denosumab) is a human monoclonal antibody and a RANK ligand inhibitor. Its new formulation is indicated for the treatment of patients with bone metastases.
Lead Product(s): Denosumab
Therapeutic Area: Oncology Product Name: Xgeva
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2024
Details:
Under the agreement, Amgen will develop, manufacture, and commercialize a subcutaneous formulation of Tepezza (teprotumumab) using Xeris’ XeriJect® technology in Thyroid Eye Disease (TED).
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Xeris Pharmaceuticals
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 10, 2024
Details:
Lumakras (sotorasib) is a small molecule, KRAS G12C inhibitor. It is approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Lead Product(s): Sotorasib
Therapeutic Area: Oncology Product Name: Lumakras
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
AMG-757 (tarlatamab) is a potential first-in-class, investigational delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE) therapy for the treatment of adult patients with advanced small cell lung cancer (SCLC).
Lead Product(s): Tarlatamab
Therapeutic Area: Oncology Product Name: AMG 757
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
The collaboration will leverage PostEra's AI platform, Proton, a pioneering innovation in generative chemistry and synthesis-aware design, and Amgen's drug discovery expertise, to advance up to 5 small molecule programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: PostEra
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 16, 2023
Details:
Wezlana (ustekinumab-auub) is a biosimilar of Stelara (ustekinumab) is approved for multiple inflammatory diseases like moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease & ulcerative colitis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: Wezlana
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
The acquisition strenghens Amgen pipeline for rare, autoimmune and severe inflammatory diseases by gaining Horizon’s first-in-class medicines like Tepezza (teprotumumab-trbw), Krystexxa (pegloticase) And Uplizna (inebilizumab-cdon).
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Horizon Therapeutics
Deal Size: $2,780.0 million Upfront Cash: $2,780.0 million
Deal Type: Acquisition October 06, 2023
Details:
The financing will be used to advance company's Generative AI pipeline of preclinical and clinical protein therapeutics, including GB-0669, a monoclonal antibody targeting a highly conserved region of the spike protein, in SARS-CoV-2.
Lead Product(s): GB-0669
Therapeutic Area: Infections and Infectious Diseases Product Name: GB-0669
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Generate Biomedicines
Deal Size: $273.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 14, 2023
Details:
ADX-914 (bempikibart) is a fully human anti-IL-7R alpha antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, which is investigated for the treatment of severe alopecia areata.
Lead Product(s): Bempikibart
Therapeutic Area: Dermatology Product Name: ADX-914
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Q32 Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
Lumakras (Sotorasib) was the first KRASG12C inhibitor to receive regulatory approval with its approval in the U.S., under accelerated approval for the treatment of metastatic KRAS G12C-mutated non-small cell lung cancer.
Lead Product(s): Sotorasib
Therapeutic Area: Oncology Product Name: Lumakras
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
